Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Lifted by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 13.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 44,901 shares of the company’s stock after acquiring an additional 5,427 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Vaxcyte were worth $3,676,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Blue Trust Inc. lifted its holdings in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the last quarter. Meeder Asset Management Inc. raised its holdings in Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares during the period. Nomura Asset Management Co. Ltd. purchased a new stake in Vaxcyte during the third quarter valued at about $92,000. Signaturefd LLC lifted its stake in Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after buying an additional 358 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Vaxcyte in the third quarter worth about $174,000. 96.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on PCVX. The Goldman Sachs Group started coverage on shares of Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of Vaxcyte in a research report on Tuesday, February 11th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $127.71.

Insider Buying and Selling

In related news, CEO Grant Pickering sold 2,366 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $92.25, for a total value of $218,263.50. Following the transaction, the chief executive officer now owns 136,215 shares in the company, valued at approximately $12,565,833.75. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at approximately $9,720,610.98. The trade was a 6.81 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,616 shares of company stock worth $6,766,481. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Stock Up 1.1 %

PCVX stock opened at $83.36 on Thursday. The company has a 50 day moving average of $85.88 and a two-hundred day moving average of $94.65. The company has a market cap of $10.39 billion, a price-to-earnings ratio of -18.12 and a beta of 0.98. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.